Growth Hormone Secretagogue

GHRP-6

5.1/10

BioHarmony verdict

Neutral

GHRP-6 is a synthetic peptide that activates the ghrelin receptor to release a pulse of your own growth hormone. It is historically pivotal but the least selective common option, with the heaviest appetite, cortisol, and prolactin effects, and no human outcome trial for body composition, per Cabrales 2013 and Locke 1995.

Read full report

What is GHRP-6?

GHRP-6, short for Growth Hormone Releasing Peptide-6, is a lab-made six-amino-acid peptide that nudges your own pituitary to release a short pulse of growth hormone. It does this by activating the ghrelin receptor, the same receptor your stomach hormone ghrelin uses, which sits on the pituitary and in the brain. It is one of the original peptides in this family, and that history is its biggest claim to importance. GHRP-6 was the research tool scientists used to clone that receptor, per Howard 1996, and that work led them straight to the discovery of ghrelin itself, per Kojima 1999. In other words, a synthetic peptide reverse-engineered an entire hormone system.

From the BioHarmony report, reviewed 2026-09-08.

How it is thought to work

Agonist at the growth-hormone secretagogue receptor (the ghrelin receptor) on the pituitary and hypothalamus

Safety watch-outs

  • Hunger so strong it derails your eating plan: reduce dose or switch to a more selective option.
  • Rising fasting glucose or new insulin-resistance signs: stop and consult a clinician, especially with diabetes.
  • Any active or suspected cancer: do not use, since growth-hormone and IGF-1 stimulation is contraindicated.
  • Signs of low mood, low libido, or breast tenderness: possible cortisol or prolactin effect, reduce dose or stop.

Full risk profile in the BioHarmony report.

Dosing as published

No approved-label or study protocol is recorded for GHRP-6 yet.

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Educator coverage (1)

Attributed viewpoints, separate from primary research.

Trust & sourcing

US approvalNot FDA approved
CompoundingFDA Category 2 for 503B use
Last checked2026-07-13
Next review2026-10-11

FDA places GHRP-6 in 503B Category 2 and identifies immunogenicity concerns plus limited safety data involving cortisol and blood-glucose effects.

Primary sources

Free guide

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.